306 related articles for article (PubMed ID: 26519872)
1. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
[TBL] [Abstract][Full Text] [Related]
2. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
Tanaka-Harada Y; Kawakami M; Oka Y; Tsuboi A; Katagiri T; Elisseeva OA; Nishida S; Shirakata T; Hosen N; Fujiki F; Murao A; Nakajima H; Oji Y; Kanda Y; Kawase I; Sugiyama H
Cancer Sci; 2010 Mar; 101(3):594-600. PubMed ID: 20132220
[TBL] [Abstract][Full Text] [Related]
3. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Wang ZD; Li D; Huang XJ
Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
[TBL] [Abstract][Full Text] [Related]
6. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
8. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
[TBL] [Abstract][Full Text] [Related]
10. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
11. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.
Steger B; Milosevic S; Doessinger G; Reuther S; Liepert A; Braeu M; Schick J; Vogt V; Schuster F; Kroell T; Busch DH; Borkhardt A; Kolb HJ; Tischer J; Buhmann R; Schmetzer H
Immunobiology; 2014 Apr; 219(4):247-60. PubMed ID: 24315637
[TBL] [Abstract][Full Text] [Related]
12. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
13. Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML.
Kim YJ; Cho SG; Lee S; Kim MS; Kim EK; Cho BS; Sohn HJ; Choi HB; Eom KS; Min CK; Kim HJ; Kim YG; Kim DW; Lee JW; Min WS; Kim CC; Kim TG
Bone Marrow Transplant; 2010 Mar; 45(3):597-9. PubMed ID: 19684628
[No Abstract] [Full Text] [Related]
14. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia.
Andersson C; Li X; Lorenz F; Golovleva I; Wahlin A; Li A
Diagn Mol Pathol; 2012 Dec; 21(4):225-33. PubMed ID: 23111196
[TBL] [Abstract][Full Text] [Related]
15. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
[TBL] [Abstract][Full Text] [Related]
16. Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation.
Rautenberg C; Pechtel S; Hildebrandt B; Betz B; Dienst A; Nachtkamp K; Kondakci M; Geyh S; Wieczorek D; Haas R; Germing U; Kobbe G; Schroeder T
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2337-2343. PubMed ID: 29753838
[TBL] [Abstract][Full Text] [Related]
17. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of human cytomegalovirus-specific CD8+ T-cells in allogeneic haematopoietic stem cell transplant recipients using pentamer and interferon-γ-enzyme-linked immunospot assays.
Liu A; Ma Y; Wu W; Chen X; Huang Y; Hu J; Liang H; Wang H; Yang R; Fan J
J Clin Virol; 2013 Oct; 58(2):427-31. PubMed ID: 23910932
[TBL] [Abstract][Full Text] [Related]
19. WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS.
Suwabe T; Shibasaki Y; Sato H; Tamura S; Katagiri T; Nemoto H; Kasami T; Kozakai T; Nanba A; Kitajima T; Fuse K; Ushiki T; Sone H; Narita M; Masuko M
Int J Hematol; 2021 May; 113(5):723-734. PubMed ID: 33502734
[TBL] [Abstract][Full Text] [Related]
20. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
